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Abstract
Extensive research efforts have been directed toward strategies for predicting risk of developing
Alzheimer’s disease (AD) prior to the appearance of observable symptoms. Existing approaches
for early detection of AD vary in terms of their efficacy, invasiveness, and ease of
implementation. Several non-invasive magnetic resonance imaging strategies have been developed
for predicting decline in cognitively healthy older adults. This review will survey a number of
studies, beginning with the development of a famous name discrimination task used to identify
neural regions that participate in semantic memory retrieval and to test predictions of several key
theories of the role of the hippocampus in memory. This task has revealed medial temporal and
neocortical contributions to recent and remote memory retrieval, and it has been used to
demonstrate compensatory neural recruitment in older adults, apolipoprotein E ε4 carriers, and
amnestic mild cognitive impairment patients. Recently, we have also found that the famous name
discrimination task provides predictive value for forecasting episodic memory decline among
asymptomatic older adults. Other studies investigating the predictive value of semantic memory
tasks will also be presented. We suggest several advantages associated with the use of semantic
processing tasks, particularly those based on person identification, in comparison to episodic
memory tasks to study AD risk. Future directions for research and potential clinical uses of
semantic memory paradigms are also discussed.
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1. Introduction
1.1 Alzheimer’s disease and prediction
Alzheimer’s disease (AD) is a worldwide health concern. It has been projected that by the
year 2050, over 100 million people worldwide will be diagnosed with AD [1], including
between 8 and 13 million individuals in the United States [2]. Currently, there are no
effective treatments for persons with AD. However, several promising strategies have been
identified that may delay or even prevent the progression of AD [3]. Various lifestyle
factors, such as dietary modifications [4] and participation in physical [5], social [6, 7], and
cognitively stimulating activities [8, 9], have been associated with a decreased risk for
developing AD. It is known that AD-related neuropathology begins to accumulate decades
prior to the onset of cognitive symptoms [10, 11]. Thus, implementation of an intervention
well before the onset of observable symptoms, such as episodic memory loss, could provide
the greatest opportunity to slow or minimize damage due to the disease, particularly if they
are targeted toward individuals with the greatest risk of developing AD.
In order to identify those individuals who are at the highest likelihood of developing the
disease, considerable research efforts have been directed toward identifying specific risk
factors and biomarkers of the disease. Two well-established risk factors for late-onset, non-
sporadic AD are a history of dementia in a first-degree relative [12] and possession of one or
more apolipoprotein (APOE) ε4 alleles [13–15]. However, these factors alone are far from
perfect in predicting who will develop the disease, and a number of studies have recently
started to identify preclinical biomarkers [16]. Cerebrospinal fluid (CSF) indices of
isoprostane [17–19], total tau and phosphorylated tau [20–22], and amyloid-β 1–42 (Aβ42)
[17, 23–25] levels have been successful in predicting conversion from mild cognitive
impairment (MCI) to AD. Additionally, neuroimaging methods have been used to predict
conversion from MCI to AD, including structural magnetic resonance imaging (sMRI) of
hippocampal volume [26–28], hippocampal rate of atrophy [29–31], and entorhinal cortex
[31–34] volume, electroencephalography (EEG) [35, 36], and positron emission tomography
(PET) using measurement of regional glucose metabolism [37–39] and amyloid imaging
[40–42].
While a number of studies have been successful in predicting conversion from MCI to AD,
predicting cognitive decline or onset of dementia in cognitively healthy older adults presents
a greater challenge. Longitudinal follow-up intervals need to be conducted over a
sufficiently long time frame to observe a clinically significant amount of cognitive decline.
Because participants are by definition cognitively intact, determination of whether
performance change over time is a reflection of test unreliability, practice effects, or age-
appropriate cognitive change can be difficult. Furthermore, clinical samples need to be large
in order to detect an adequate number of participants who actually do show cognitive
decline. Given the expense of neuroimaging methods, it is often difficult to dedicate the
resources necessary to studies of this magnitude. Hence, most longitudinal neuroimaging
studies to date have attempted to predict conversion of MCI to AD. However, for
interventions to be maximally effective in altering the disease course of AD, earlier
identification of AD risk is essential. Advanced neuroimaging methodologies have
considerable potential to function as biomarkers of risk. Therefore, longitudinal
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neuroimaging studies focusing on prediction of cognitive decline in cognitively intact older
adults are needed to further evaluate and implement this potential.
1.2 Functional magnetic resonance imaging of risk and prognosis
Functional magnetic resonance imaging (fMRI) has considerable promise as an effective
preclinical biomarker of AD. Because task-activated fMRI relies on the capability to carry
out specific cognitive tasks, it is sensitive to the dynamic functional integrity of the brain.
Therefore, fMRI may be able to reveal early abnormalities in brain function that could
reflect the initial stages of AD neuropathology. Indeed, analysis of the task-activated blood-
oxygen-level-dependent (BOLD) signal has yielded successful prediction of conversion
from MCI to AD [43–45]. A limited number of studies have also used fMRI to predict
subsequent cognitive decline in cognitively intact older adults [46–50]. Having a genetic
predisposition to develop AD has been demonstrated to influence the BOLD signal in
asymptomatic older adults [51–53]. Similar risk-related alterations of the BOLD signal have
been observed throughout adulthood [54–58], suggesting that factors including the APOE ε4
allele and a family history of AD influence brain functioning across the lifespan. Given
these factors, fMRI biomarkers may allow for more accurate prediction of cognitive decline
over sMRI, family history, and APOE genotype information alone [48].
1.3 Overview
In this review, we will present a summary of work from cross-sectional and longitudinal
studies investigating imaging strategies for early detection of cognitive decline. Our
collaborative research group has focused on identification of the neural correlates of
semantic memory to investigate early prediction of cognitive decline. Using person-identity
memory as a foundation, we evaluated face and name discrimination and subsequently
developed a famous name discrimination task. fMRI activation associated with this task has
successfully differentiated younger control participants from cognitively intact older adults
[59], healthy older APOE ε4 carriers from non-carriers [52], and persons with amnestic MCI
from older healthy and at-risk controls [60]. The task has also assisted in contrasting theories
of age-related neural network change [59, 61, 62], to evaluate hypotheses regarding the
relative roles of the neocortex and the medial temporal lobe in the retrieval of recent and
remote semantic memories, and to investigate the nature of temporally graded remote
memory retrieval [61, 62]. Recently, we have developed a prediction model to assist in
identifying cognitively intact older adults who were at the greatest risk of cognitive decline
[48], and we evaluated the effects of self-reported physical activity on alteration of semantic
memory activation in healthy older adults [63] and MCI patients [64].
Our results, in addition to research findings from several other laboratories, suggest that
fMRI during semantic processing tasks may provide advantages over episodic memory tasks
in the assessment of risk for AD and prognosis for future cognitive decline. The present
work will review research conducted by our lab and others on the functional correlates of
semantic memory with regard to aging, AD risk, cognitive decline, and MCI. Future
directions for research and the viability of fMRI in a clinical setting will also be discussed.
2. Semantic Memory Task Development, Results and Implications for
Memory Theories
2.1 Episodic v. semantic memory in AD biomarker research
A number of fMRI studies engage participants in various tasks involving aspects of memory
functioning. Two general categories of memory performance are frequently assessed –
episodic memory (e.g. discriminating between previously learned and novel stimuli) and
semantic (recall of general facts and knowledge about the world that is not contextually
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specific, e.g. making a categorical or attributional judgment to a presented item). Given that
episodic memory impairment is a hallmark of AD [65], most fMRI studies of AD risk have
used episodic memory tasks [53]. However, the use of episodic memory tasks in fMRI
studies that focus on prediction of MCI, AD, and risk factors for these conditions may
present challenges. Episodic memory impairment is typically observed not only in
association with symptom onset of MCI or AD [66–70], but declines in episodic memory
performance are also observed in normal aging [71]. Therefore, disparities in task
performance between participants and groups may confound results. Discrepancies in the
BOLD signal between participants during episodic memory tasks may therefore be a product
of neuropathology or age-related differences in task performance (or both). However, for the
purposes of fMRI biomarker research, the question of interest focuses primarily on the
extent to which neuropathology influences the brain’s hemodynamic response during
cognitive processing; imaging is not necessary to assess age-related memory performance
differences. Furthermore, episodic memory tasks may also be inherently more difficult than
semantic memory tasks, and individuals who are in the preliminary stages of cognitive
decline may exert greater effort and may paradoxically display a greater BOLD signal [72]
due to the increased cognitive challenge. Indeed, in longitudinal studies utilizing episodic
memory tasks, participants who display a greater extent of activation are typically at the
greatest risk of subsequent cognitive decline [46, 49, 50].
The use of semantic memory tasks during fMRI may provide several advantages over
episodic tasks. Semantic memory tasks involve immediate, context-independent familiarity
with previously learned information, and they are typically easier and less frustrating for
older participants to complete than episodic tasks. Unlike episodic memory skills, semantic
memory abilities remain relatively intact with normal aging [71] but are commonly affected
during AD [73–75]. In studies of risk, between-group discrepancies in task performance are
not frequently observed, because all participants can perform with a high degree of accuracy
[48, 52]. Contrary to the results from longitudinal episodic memory studies [46, 49, 50],
participants who exhibit lower activation during semantic tasks appear to be at the greatest
risk of future cognitive decline [47, 48]. Furthermore, regions that are typically activated
during semantic memory retrieval overlap with those associated with the default mode
network [76] as well as with regions that are the most susceptible to neuropathological
changes associated with AD [77]. Thus, analysis of the BOLD signal during semantic
memory processing has a number of advantages over episodic memory for discriminating
between healthy aging and disease-related changes and risk.
Several semantic processing tasks have been utilized in functional imaging studies. The
most common contrasts [76] include semantic versus phonological word judgments (e.g.
[78, 79]), discriminating between words and pseudowords (e.g. [80, 81]), high versus low
meaningfulness judgments (e.g. related and unrelated word pairs, [82, 83]), and comparing
members of specific categories (e.g. concrete or abstract words, [84, 85]). Considerable
research has also been dedicated to tasks involving person identity, such as the recognition
of famous and unfamiliar names or faces [86–92], which reflects a semantic meaningfulness
dimension (e.g., meaningful vs. non-meaningful) [76]. When contrasting the recognition of
famous names with the correct rejection of unfamiliar names, activation has been observed
in a variety of neocortical and medial temporal lobe (MTL) regions, including the
hippocampus [61, 62]. Our research has focused on this paradigm to investigate the neural
correlates of person identity and memories of different ages, and how these processes may
be affected by aging and risk for AD. In the following sections, we describe the
development and preliminary usage of our famous and unfamiliar name stimuli.
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2.2 Episodic and semantic memory networks during face recognition
The first study of the long-term, semantic memory network by our group [93] involved the
use of fMRI during familiarity judgments of famous and recently learned faces. Our initial
focus was to contrast the neural correlates of semantic and episodic memory with regard to
person identity. Participants were instructed to learn and remember novel, unfamiliar
pictures of faces during an encoding phase. During a retrieval phase, participants were asked
to determine whether a presented face was familiar or unfamiliar. Familiar faces were either
previously seen during the encoding phase or were famous individuals, and unfamiliar faces
were non-famous foils. The famous faces consisted of well-known entertainers, politicians,
and sports figures from the previous 30 years. Thus, this paradigm allowed for direct
comparison between the neural networks associated with two distinct retrieval memory
systems: newly learned episodic memory (from the encoding phase) and long-term semantic
memory (famous faces).
Compared to the correct rejection of unfamiliar faces, recognition of newly learned faces
induced a left-lateralized cortical pattern of fMRI activation. Greater activation was
observed for unfamiliar faces over newly learned faces in several bilateral frontal regions
and the right fusiform gyrus. In contrast, recognition of famous faces activated an extensive
bilateral network incorporating both cortical and subcortical regions, compared to newly
learned and unfamiliar faces. Importantly, greater activation was observed in MTL
structures, including the left hippocampus and right parahippocampal gyrus. Behavioral
differences could not account for the discrepancy in neural recruitment between newly
learned and famous faces. Thus, this low effort, high accuracy semantic processing task,
which is usable in large segments of the population due to the high familiarity of the stimuli,
activated an extensive bilateral network associated with the recognition of well-known
individuals.
A critical question of interest is whether pictures of faces and written names of familiar
individuals are processed in similar brain regions or whether the mental representation of
this person-identity material may engage different brain regions. In addition, face stimuli
tend to contain complex visual information, including affective valence (e.g., the individual
is typically smiling), variations along an attractiveness continuum, and other visual details
(e.g., hair style, presence of facial hair, clothing). Name stimuli tend to be more uniform in
terms of the visual stimulus that is presented (i.e., letters). Therefore, name stimuli may have
advantages over face stimuli in terms of reducing the complexity of the material presented to
participants. The ability to present names of individuals who became famous in different
eras also affords the opportunity to explore the brain’s responses during activation of
memories of different ages.
2.3 Development and pilot testing of famous names
We sought to identify the patterns of neural activity associated with the recognition of
persons from different time periods to determine whether the brain exhibits a temporally
graded pattern of regional recruitment in response to memories of different ages. To address
these questions, we developed a list of famous and unfamiliar names that could be reliably
categorized by older and younger individuals alike [62]. We identified entertainers,
politicians, criminals, or athletes who achieved public prominence either between
approximately 1990 and 2000 (Recent famous names) or between approximately 1950 and
1965 (Remote famous names). Unfamiliar names were randomly selected from a local
phone book as a control condition. Following pilot testing with older and younger adults, we
created a final list of 30 names in each of four categories. Unfamiliar names were selected
for inclusion on the final list if they were correctly identified as non-famous by 90% of both
older and younger participants. Recent famous names from the 1990’s (e.g. George
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Clooney, Colin Powell) were correctly identified as famous by at least 90% of both younger
and older adults. Enduring famous names (individuals who achieved fame between 1950 and
1965 and are still well known today; e.g., John F. Kennedy, Marilyn Monroe) were also
correctly identified as famous by at least 90% of both younger and older adults. Our fourth
category, Remote famous names, consisted of individuals who achieved fame between 1950
and 1965 but who were correctly identified by at least 90% of older adults and by no more
than 30% of younger participants. This latter stimulus category was designed to represent
famous names that would be easily recognizable to older adults while being out of the public
eye for several decades. Therefore, correct identification of these stimuli was thought to
reflect retrieval of remote semantic material without being contaminated by recent updating.
In this task, participants are required to categorize each name as famous or unfamiliar. Thus,
the task is known as the famous name discrimination task (FNDT).
2.4 Famous name recognition of recent and remote memories
Our initial study using the FNDT investigated functional activity specifically in the
hippocampal complex and parahippocampal gyrus (PHG) in response to Recent, Remote,
and Unfamiliar names [62]. A goal of this study was to contrast predictions of two models of
hippocampal functioning: Hippocampal Consolidation [94] and Multiple Trace Theory [95].
According to the Hippocampal Consolidation model, the hippocampus guides the formation
of memory representations in the neocortex and serves only a time-limited role in memory
retrieval. In contrast, Multiple Trace Theory posits that successful memory retrieval relies
on the interaction between the hippocampus and neocortex, and the hippocampus is involved
as long as the memory is available. Analysis of memories of different ages, such as the
recognition of famous names from Recent and Remote time periods, presents the
opportunity to test these competing theories. The Hippocampal Consolidation model would
predict that hippocampal activation would be observed for Recent but not Remote names,
and Multiple Trace Theory predicts that hippocampal activation would be seen in response
to names from both time epochs.
Cognitively intact older adults completed the FNDT during event-related task-activated
fMRI. Bilateral activation was observed in both the hippocampus and PHG during both
Recent and Remote name recognition compared to Unfamiliar names, substantiating the
participation of MTL structures during long-term recognition memory. However, a
temporally graded retrieval pattern was observed in the right MTL, but not in the left MTL.
That is, greater activation in both the right hippocampus and PHG was observed during
recognition of Recent famous names relative to Remote famous names. No significant
activation differences between Recent and Remote famous names were observed in the left
MTL (Figure 1).
A subsequent report [61] utilizing the same imaging dataset examined patterns of
neocortical activation associated with the recognition of Recent and Remote famous names.
Both Recent and Remote names recruited an extensive bilateral pattern of cortical regions
compared to Unfamiliar names, including regions in the frontal, temporal and parietal lobes.
A temporally graded retrieval pattern was also observed in posterior cingulate cortex (PCC),
with greater activation during Recent compared to Remote name recognition (Figure 2). The
PCC has extensive connections to frontal cortex [96] as well as to the MTL [97–99], and it
appears to play a major role in the neural circuitry involved in both episodic [100] and
semantic [76] memory retrieval. Additionally, a number of studies have demonstrated
hypometabolism, hypoperfusion, or decreased activation in the PCC in individuals with MCI
[38, 101] or AD [102–104].
The findings of these two studies [61, 62] have implications regarding the relative
contributions of MTL and cortical regions during memory retrieval. The MTL activation
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associated with famous name recognition memory [62] primarily supported the Multiple
Trace Theory [95] of hippocampal functioning, because greater hippocampal complex
activity was observed during correct identification of both Recent and Remote famous
names relative to the rejection of Unfamiliar names. However, evidence of temporally
graded memory retrieval observed in the right MTL and PCC also provided some support
for the Hippocampal Consolidation theory [94]. Because Remote famous names elicited less
hippocampal activation than Recent names, this pattern suggests that older memories may be
predominantly stored in neocortical rather than in hippocampal regions. A similar pattern of
temporally graded activity in the MTL during famous face recognition has also been
reported, with greater activation in response to recently learned faces being observed in the
right entorhinal cortex [91]. However, evidence supporting the presence of a temporal
gradient in the hippocampus during famous face recognition has been mixed, with one study
observing no difference between recent and remote faces [89] and another showing greater
activation in response to recent faces in right hippocampus only [91]. Despite these mixed
findings associated with the temporal gradient, identification of famous faces and names
appears to reliably engage both hippocampal and neocortical regions. Differences across
studies in the definitions of recent and remote time epochs and the nature of the stimuli
themselves (e.g. visual characteristics of face stimuli) could possibly account for the
variability in findings. Robust evidence supporting evidence of hippocampal consolidation
model has been demonstrated using episodic recognition of newly-learned photographs over
a 3-month interval [105].
2.5 Face vs. name recognition
Differences in the activation pattern between famous names and famous faces noted across
the studies described above prompted us to investigate whether there are common and/or
unique neural network components subserving famous face and name recognition [106].
Using the stimuli described earlier [59, 93], young adult participants viewed famous and
unfamiliar faces and names during task-activated fMRI. Although recognition performance
exceeded 90% for all stimulus types, accuracy was significantly better for names than for
faces. Collapsed across famous and unfamiliar stimuli, each presentation modality activated
distinct regions, most notably bilateral fusiform and lateral occipital regions for faces
relative to names and diffuse left neocortical regions for names relative to faces. However,
when collapsed across stimulus type, there was a distinct pattern of overlapping neural
activation for famous compared to unfamiliar stimuli. This “fame network” consisted of
bilateral hippocampal regions in addition to regions in the left frontal, insular, temporal, and
parietal lobes, and posterior cingulate. The presence of common regions between both
famous face and name recognition suggests that these areas are involved with person
identity semantic memory, regardless of presentation modality. The preceding studies were
helpful in validating the FNDT for use in studying semantic memory processes associated
with person-identity information and enabled us to investigate aspects of the cognitive
neuroscience associated with fame recognition. The following sections will discuss the use
of the FNDT and semantic memory activity in the study of normal and pathological aging.
3. Integrity of semantic processing as a biomarker
3.1 Age-related differences in semantic processing
Previous neuroimaging research has demonstrated that compared to younger adults, older
adults typically display a more widespread pattern of fMRI activation with reduced
hemispheric asymmetry [107, 108]. A potential explanation for these findings is that
increased activation represents compensatory recruitment of additional resources to achieve
equivalent cognitive performance, despite declining brain function. An alternative but not
mutually exclusive hypothesis suggests that the specialization of neural regions decreases
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with age, resulting in dedifferentiated, more diffuse patterns of activation. Using the FNDT,
we have observed similar compensatory patterns of increased fMRI activity during semantic
memory retrieval in older compared to younger adults [59].
Younger and older adult participants completed the FNDT during fMRI. In 15 out of 20
neocortical and MTL regions (including the right hippocampus), older adults exhibited a
greater magnitude and spatial extent of activation than younger adults. Younger adults did
not demonstrate greater activation than older participants in any region. The difference
between groups was particularly large for Recent names, with greater activation observed
for older adults in all 15 regions, whereas greater activation for Enduring names was
observed in 7 out of the 15 regions. The selectively greater activation observed in older
compared to younger adults provides evidence for compensatory recruitment during
semantic memory retrieval, even though task accuracy was comparable to younger adults.
These findings stand somewhat in contrast to other studies of semantic processing and
aging. One study [109] observed reduced activation in older compared to younger
participants during a semantic word judgment task (concrete vs. abstract) in left prefrontal
cortex, and older participants did not recruit additional regions compared to younger adults.
Another study [110] reported that younger and older adults recruited mainly overlapping
regions of neocortex during semantic word encoding (living vs. non-living), but a greater
magnitude of activation in younger adults was observed in the left hippocampus. The
authors of these studies argue that frontal and MTL regions subserving semantic encoding
may be functionally deficient in older adults. Although compensatory recruitment was not
observed in these studies, the hypothesized functional deficiencies may help to explain why
additional regions appear to have been recruited in other fMRI studies assessing episodic
memory [107] or the FNDT [59].
3.2 Evidence for compensatory recruitment associated with risk for AD
According to the Scaffolding Theory of Aging and Cognition (STAC; [108]), the
recruitment of additional neural circuitry during task performance occurs to support
structures with declining functional integrity. This additional recruitment may reflect an
essential component of healthy, adaptive cognitive aging. For example, a study using PET
[111] observed greater hemispheric asymmetry during an episodic memory task in older
adults who performed well compared to those who did poorly on the task, suggesting that
“scaffolding” is beneficial for maintaining late-life cognition. Another study [112] observed
that increased prefrontal activity in AD patients was correlated with better performance on
both episodic and semantic memory tasks. Such scaffolding may occur across the lifespan,
although in older individuals this adaptation may be more common and necessary due to the
accumulated deterioration of neural circuitry. The additional recruitment in response to task
demands is reflected by increased regional brain activation.
Scaffolding has been observed in those at the greatest risk for late-life degenerative
conditions, such as AD, prior to the onset of clinical symptoms. For example, one study [51]
observed greater magnitude and spatial extent of activation during an episodic picture
encoding task in older adults who were carriers of the APOE ε 4 allele compared to non-
carriers, even though all participants were non-demented and had normal memory
functioning. A similar compensatory response was observed in right hemisphere regions of
older, non-demented APOE ε 4 carriers during a verbal episodic encoding task compared to
non-carriers [113]. This risk-related scaffolding pattern has been observed to occur
throughout middle age and late-life. In a cross-sectional study [56], right hippocampal
activation during episodic encoding decreased with age in low risk participants (APOE ε 4
non-carriers without a first-degree family history of dementia). However, right hippocampal
activation increased with age in APOE ε 4 carriers and those with a family history of
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dementia, with the greatest increases observed in persons with both risk factors.
Furthermore, greater bilateral hippocampal activation has been observed in young adult
APOE ε 4 carriers compared to non-carriers during episodic picture encoding [57].
Not all studies examining the effects of the APOE ε 4 allele have observed increased
recruitment. Some studies have observed a reduced signal in APOE ε 4 carriers [114, 115],
whereas other studies reported no differences between groups [116, 117]. The nature of the
effects may vary with the choice of task, stimuli, or region studied [53]. However, these
studies of altered patterns of activation associated with risk factors for dementia are
consistent with evidence that AD pathology may accumulate over decades prior to clinical
onset [10, 11]. According to STAC, the compensatory recruitment pattern would imply that
possession of these risk factors is associated with declining functional integrity despite
equivalent task performance.
Limited research has examined the effects of risk on functional activation during semantic
memory processing. One study [118] reported decreased activity in APOE ε 4 carriers
compared to non-carriers during a word categorization paradigm relative to a baseline
passive fixation condition, in regions in the anterior cingulate and left parietal lobe.
However, a follow-up report from the same dataset [119] indicated that APOE ε4 carriers
had reduced deactivation from baseline due to abnormalities in the default mode (or “resting
state”) network. Thus, the interpretation of the previous study [118] is tempered by the
choice of passive fixation as a comparison condition. Using the FNDT, which uses active
identification of unfamiliar names as a comparison condition for active recognition of
famous names, we observed evidence of compensatory recruitment in asymptomatic older
adults at-risk for AD during semantic memory processing [52].
Cognitively intact older adults were divided into three groups based on genetic risk for AD:
APOE ε 4 carriers with a family history of dementia in a first degree relative (FH+ε4),
APOE ε 4 non-carriers with a family history of dementia (FH), and control participants with
neither risk factor (CON). During the FNDT, both at-risk groups demonstrated nearly
completely independent regions of activation from the control group. Moreover, the control
group displayed predominantly greater activation during the presentation of unfamiliar
names, whereas the at-risk groups had a greater response to famous names. Overall, the FH
+ε 4 had a greater volume of activation in response to famous relative to unfamiliar names
than the FH group (Figure 3). The results of this study are consistent with the
aforementioned studies that demonstrated the impact of risk factors for AD on the BOLD
signal prior to the onset of cognitive symptoms. The additional neural recruitment observed
during semantic memory retrieval in those at genetic risk for AD provides evidence
supporting STAC and the declining integrity of neural resources in these individuals.
Moreover, the impact of risk factors appeared to be additive, with the greatest functional
recruitment being observed in individuals with both risk factors. These results could not be
explained by differences in task performance or effort, as all groups exhibited equivalent
accuracy and reaction times. Importantly, the striking differences in brain activation maps
between persons with and without risk factors for AD highlighted the potential use of the
FNDT as a method for assessing presymptomatic dementia risk. However, limitations of this
and other studies of risk include that they are cross-sectional, and the altered activation
patterns are not necessarily evidence of increased risk. Longitudinal studies are necessary to
determine the predictive utility of fMRI (discussed in section 3.4).
3.3 Altered activation in MCI patients
In addition to revealing early abnormalities in patterns of activation that may reflect AD risk
in cognitively intact older adults, altered semantic memory processing has been reported in
individuals with MCI. A diagnosis of MCI typically precedes AD, although not all cases
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will progress to dementia [120]. MCI is characterized by deficits in both episodic and
semantic memory systems[121, 122]. Several previous fMRI studies have observed
differences in the BOLD signal associated with episodic memory processing between MCI
patients and age-matched controls [123–127]. However, it should be noted that these studies
used generally effortful episodic memory tasks, and in one study [127], MCI patients
performed significantly worse than controls. While this discrepancy in performance was not
universally observed in the aforementioned studies, it is nonetheless difficult to interpret
between-group fMRI data when differences in motivation and cognitive performance are
potential confounds [128]. The use of a low effort, high accuracy task provides advantages
for the examination of MCI-related alterations to the BOLD signal, because all subjects can
perform at high levels. One previous study [129] utilized a lexical decision task that MCI
patients were able to perform with comparable accuracy relative to controls. The results
revealed a differential pattern of activation between groups, including hyperactivation in
bilateral anterior cingulate cortex and hypoactivation in bilateral fusiform and left
occipitotemporal and inferior frontal regions in MCI patients relative to controls.
Furthermore, there was no evidence of atrophy in these regions in the MCI patients. Another
study [130] investigated fMRI activation during a semantic word association task and
observed equivalent performance between MCI patients and controls. Compared to a size
discrimination control condition, MCI patients displayed hypoactivation relative to controls
in the posterior third of the lower bank of the superior temporal sulcus. The results of these
studies suggest that patterns of fMRI activation can reliably identify abnormal functioning in
neocortical regions and can be used to distinguish between MCI patients and cognitively
intact older adults, even when task performance is comparable.
We demonstrated evidence of compensatory recruitment during semantic memory retrieval
in MCI patients using the FNDT [60]. Older adults with MCI (according to Petersen criteria
[131]) and cognitively intact controls with or without the APOE ε 4 allele (“high-risk” and
“low-risk” groups, respectively) served as study participants. Importantly, the three groups
did not differ on task performance. Consistent with our previous work [52], high-risk
controls displayed greater activation than low-risk controls for famous relative to unfamiliar
names in several MTL and neocortical regions. Interestingly, MCI patients displayed a
similar compensatory response, with a greater extent and magnitude of activation across a
number of brain regions compared to both high- and low-risk controls.
This study [60] demonstrated evidence for compensatory recruitment and/or scaffolding,
which may reflect compensation for functional deficits in the neural networks subserving
semantic memory in MCI patients. Importantly, these differences were observed when task
performance was equivalent between groups. While semantic memory impairment is
commonly associated with MCI [121, 122], our participants were still able to perform this
relatively simple task at a high level of accuracy. Thus, activation associated with semantic
processing of person-identity information can be used to identify abnormal patterns of
activation in older individuals who have experienced cognitive impairment. Subsequent
research from our group has focused on evaluating the FNDT for use as a predictor of
cognitive decline in asymptomatic older adults.
3.4 Longitudinal prediction of cognitive decline
A limited number of longitudinal studies (see section 1.1) have attempted to use patterns of
fMRI activation to predict cognitive decline in cognitively intact older adults [46, 47, 49,
50]. In many of these studies, greater activation in left [46] or right [49] hemispheric regions
or hippocampus [50] at baseline was indicative of an increased risk for subsequent decline.
Other longitudinal studies [43, 44] have examined the value of task-activated fMRI for the
prediction of the conversion from MCI to AD. In these studies, greater activation was again
associated with a poorer prognosis, either when observed in the hippocampus during
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episodic encoding [43] or in parietal regions during an angle discrimination task [44]. We
recently reported contrasting findings from a longitudinal prediction study utilizing a
semantic processing task [48].
Cognitively intact older adults were compared on neuropsychological testing, sMRI, and the
FNDT during fMRI at baseline versus at 18-month follow-up. Participants were recruited
from newspaper advertisements, and half were selected on the basis of a family history of
dementia in a first-degree relative. Thus, our sample was enriched with a greater proportion
of APOE ε4 carriers than in the general population, as this allele is more common in
individuals with a family history of dementia [54, 132]. At follow-up, 34.6% of participants
exhibited cognitive decline, defined as a performance deficit of at least one SD compared to
the predicted value on one or more of three neuropsychological outcome measures (Mattis
Dementia Rating Scale-2 [133–135], Rey Auditory Verbal Learning Test (AVLT) Sum of
Trials 1–5 and AVLT Delayed Recall [136]). Given the relatively brief follow-up period, the
purpose of this study was not to predict cognitive impairment or MCI status (only 7.4% of
declining participants met Petersen criteria for MCI [131] after 18 months), but rather to
predict a one SD or greater decline in performance that may represent the early phases of
MCI or dementia. Although it is possible that other factors may have accounted for decline
in some participants, the majority of participants who declined by one SD at follow-up
continued to exhibit decline at five-year follow-up (unpublished data).
Stable and declining participants had equivalent FNDT performance at baseline. Notably,
participants with greater fMRI activation at baseline were less likely to have exhibited
cognitive decline at follow-up. Logistic regression analyses demonstrated that lower
activation during the FNDT in cortical and hippocampal regions, smaller bilateral
hippocampal volume (as determined by manually-traced sMRI), and presence of the APOE
ε 4 allele were each independently associated with a greater risk of cognitive decline at 18-
month follow-up (Figure 4). Thus, baseline semantic memory activation provided predictive
information regarding future cognitive decline above and beyond genetic risk and
hippocampal atrophy. Even though the reduced hippocampal activation in the declining
group may have been due to atrophy, the activation still functioned as an independent
predictor of decline. Consistent with our cross-sectional studies [52, 60], carriers of the
APOE ε 4 allele displayed greater activation in response to famous relative to unfamiliar
names at baseline than non-carriers. However, for both APOE ε 4 carriers and non-carriers,
greater BOLD signal activation was associated with a reduced probability of decline.
These results appear to contradict previous longitudinal studies that used fMRI to predict
cognitive decline [46, 50], where greater baseline activation was associated with a poorer
prognosis. However, an important difference in our study was the use of a low effort, high
accuracy semantic memory paradigm, as opposed to an episodic memory task. Our results
are consistent with another longitudinal study that observed that greater activation in a left
parietal region during semantic word classification was associated with a reduced incidence
of future cognitive decline [47]. Because episodic tasks are cognitively demanding, greater
activation in declining participants could reflect the additional cognitive effort necessary to
complete the tasks. This additional exertion could be the product of declining functional
integrity in neural resources, hence the greater probability of subsequent cognitive decline.
In contrast, greater fMRI activation during semantic processing tasks could represent a
healthy, adaptive response to combat declining neural resources that is protective against
future degeneration, consistent with STAC [108].
Recently, we reported advantages of semantic processing tasks over episodic memory tasks
for the prediction of cognitive decline [137], which may have important implications for the
use of fMRI as a clinical biomarker for cognitive decline and dementia. The participants
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from our longitudinal study [48] completed an episodic memory task at baseline after the
semantic task, during which they were required to discriminate between names presented
during the semantic trial and novel famous and unfamiliar names. Accuracy was equivalent
between cognitively stable and declining participants for all stimulus conditions, although
accuracy was much poorer for the episodic task.
A principal components analysis revealed a network of subcortical, parietal/temporal, and
frontal activation associated with identification of previously seen relative to novel names.
Logistic regression analyses revealed that only increased subcortical activation (including
bilateral caudate and thalamus) was associated with a higher predicted probability of
decline. However, the predictive utility of the episodic memory-induced fMRI regional
activation components was inferior to the regional activation induced by the FNDT. The
semantic task’s enhanced sensitivity to probability of future decline may be due in part to
the overlap between the semantic memory and default mode networks [76].
In a recent meta-analysis of fMRI studies using semantic processing tasks [76], a left-
lateralized network was identified as being crucial to semantic retrieval. This network
included seven regions – posterior inferior parietal lobe, middle temporal gyrus, fusiform
and parahippocampal gyri, dorsomedial prefrontal cortex, inferior frontal gyrus,
ventromedial prefrontal cortex, and posterior cingulate gyrus. We have observed activation
in all of these regions when contrasting famous relative to unfamiliar name recognition with
the FNDT [61]. Additionally, this meta-analysis suggested that these regions appear to
overlap with areas commonly associated with the default mode, or “resting state” network
[76]. This network typically displays deactivation during task engagement in healthy
controls, and reduced task-activated inhibition of the default mode network has been
observed in older compared to younger adults [138], as well as in MCI and AD patients
compared to age-matched controls [138, 139]. Furthermore, reductions in default mode
deactivation have been observed in asymptomatic APOE ε 4 carriers compared to non-
carriers [57] and have been associated with an increased risk for the conversion from MCI to
AD [45]. One group [77] noted that regions commonly associated with the default mode
network parallel the regional distribution of amyloid-beta plaques that are common in the
early phases of AD, and they postulated that the continuous activity of these regions
throughout life may increase the susceptibility to this late-life pathology. This “Metabolism
Hypothesis” would imply that overuse of these regions confers a greater risk for AD
pathology. Given the overlap between the semantic memory and default mode networks
[76], this assertion may help to explain why semantic memory tasks are sensitive to AD risk
and likelihood of cognitive decline.
3.5 Associations with physical activity
Our review of the literature suggests that task-activated fMRI provides predictive
information concerning cognitive decline in asymptomatic older adults. Various other
biomarkers [16] and lifestyle behaviors [3] have been identified as risk factors for cognitive
decline and AD. Thus, the most effective combination for prediction models may consist of
fMRI combined with other variables. One area of research has investigated the influence of
physical activity (PA), which has been identified as a possible protective factor involved in
maintaining late-life cognitive functioning [5]. Although the specific neural mechanisms by
which PA might confer resistance to decline are still largely unknown, some candidates have
emerged. Exercise interventions (such as wheel running) in rodents increase levels of brain-
derived neurotrophic factor (BDNF), which, in turn, promotes synaptogenesis, neurogenesis,
and plasticity [140–144].
Recently, PA has been demonstrated to increase brain tissue volume in older humans,
potentially as a result of exercise-mediated neurogenesis [145]. Physically inactive elderly
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adults were randomly assigned to aerobic exercise (walking) or stretching (control)
conditions. At six-month and one-year follow-up, bilateral hippocampal volume as
measured by sMRI increased in the aerobic exercise group, whereas hippocampal volume
decreased in the stretching group. The greatest differences were observed in bilateral
anterior hippocampus, which contains the dentate gyrus, a site of adult neurogenesis [140].
Moreover, elevations in serum BDNF compared to baseline were associated with greater
volume increases in bilateral anterior hippocampus, substantiating the role of neurogenesis
as a potential mechanism by which PA may delay AD-related neuropathology and
hippocampal atrophy. Additionally, the aerobic exercise group displayed an improvement in
spatial memory abilities compared to control participants.
We recently observed fMRI evidence of the protective effects of PA on brain functioning
[63]. Using a previously validated measure of PA for older adults (the Stanford Brief
Activities Survey; [146, 147]), we separated cognitively intact older adults into four groups:
Low Risk/Low PA, Low Risk/High PA, High Risk/Low PA, and High Risk/High PA. Risk
was defined as the presence or absence of the APOE ε 4 allele. Consistent with our previous
research [48, 52, 60], High Risk participants displayed a greater extent and magnitude of
activation compared to Low Risk individuals during the FNDT. Interestingly, High PA
participants displayed greater semantic memory activation than Low PA in several frontal
and temporal regions. Furthermore, an interaction between risk and PA indicated that the
elevated activation associated with engagement in PA was greater for High Risk than Low
Risk participants. Interaction effects (defined as a familywise error threshold of p < .01)
were observed in predominately left hemisphere neocortical regions (Figure 5). Combined
with our previous longitudinal study [48], these findings imply that High PA participants
may be at reduced risk for cognitive decline, with the beneficial effects of PA being
potentiated in those at genetic risk for dementia.
A follow-up study [148] supported the prognostic implications of the relationship between
PA and the BOLD signal. PA was added as a variable to the 18-month prediction models
developed from the participants from our longitudinal study [48]. In a model including
hippocampal activation, APOE ε 4 allele status, PA, and the interaction between APOE and
PA, PA alone was not a significant predictor of cognitive decline, but the interaction effect
was significant. This result indicated that PA can provide information regarding prognosis
for cognitive decline beyond genetic and fMRI variables alone. Analysis of the simple
effects revealed that the protective effects of PA in reducing the probability of cognitive
decline were limited to APOE ε 4 carriers, in concordance with the results of our previous
study [63]. Moreover, in APOE ε 4 carriers, the effects of PA were non-significant in
participants with below average (in our sample) hippocampal volume or semantic memory
activation, suggesting that PA may be more beneficial for older adults with strong
hippocampal integrity. Thus, information concerning leisure engagement in PA may
enhance prediction of cognitive decline over fMRI, sMRI, and genetic variables alone, and
optimal prediction may include the assessment of several factors.
The enhanced protective effects of PA for APOE ε 4 carriers compared to non-carriers have
been reported in other studies as well [149–151], although one notable study found the
opposite interaction. In that longitudinal study, greater engagement in PA was associated
with a reduced risk for dementia in APOE ε 4 non-carriers only [152]. Further research is
necessary to determine the exact nature of this interaction, but at present, our results suggest
that the potential of PA as a late-life intervention to delay or prevent cognitive decline may
be limited (or at least maximally beneficial) to those at genetic risk for AD.
A recent report by our group also suggests that PA may be protective against further
cognitive decline in amnestic MCI patients [64]. Nine Low PA and nine High PA MCI
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patients, matched on demographic variables, completed the FNDT. Greater activation for
famous relative to unfamiliar names was observed in High PA compared to Low PA
participants in the left caudate nucleus. Reductions in caudate volume have been associated
with MCI and an increased risk for conversion to AD [153, 154]. These results suggest that
PA may assist in preserving caudate integrity and may reduce the risk of conversion to AD,
even though no group differences were observed in caudate volume in our sample. A
longitudinal follow-up is necessary to assess the validity of this postulation. A limitation of
this study and the other PA studies by our group [63, 148] is that our measure of PA [146,
147] is based on self-report, and the studies are purely observational in nature. Controlled
intervention studies are necessary to validate the protective value of PA for the late-life
maintenance of cognitive functioning.
4. Summary and future directions
4.1 Semantic memory probes as a clinical biomarker
The use of a low effort, high accuracy task that recruits a semantic memory network during
task-activated fMRI may be beneficial for studying healthy and degenerative aging
processes. The FNDT can be used to study activation attributable to memories of different
ages and can reveal the involvement of MTL structures during memory retrieval of recent
and remote material. Semantic processing paradigms have also successfully demonstrated
evidence of compensatory recruitment and/or cognitive scaffolding in older compared to
younger adults [59], amnestic MCI patients [60], and those at the greatest risk for AD [52].
Eighteen-month follow-up suggests that greater functional activation during the FNDT in
cortical and hippocampal brain regions is associated with a reduced probability of cognitive
decline [48]. This finding suggests that cognitive scaffolding [108] may be a protective
adaptation to combat the declining functional integrity of neural resources that occurs with
normal and pathological aging. There are also indications from this work that fMRI
activation during semantic processing tasks may be advantageous over episodic memory
paradigms for identifying individuals who are at the greatest risk of cognitive decline [137].
The most effective model for prediction of cognitive decline consisted of fMRI activation
during semantic memory processing in cortical and hippocampal regions and APOE allele
status [48]. Reduced baseline hippocampal volume was also related to cognitive decline in a
separate model. Last, we reported that engagement in PA was associated with greater task-
induced fMRI semantic memory activation [63], which may confer resistance to cognitive
decline. However, these benefits may be limited to or enhanced in APOE ε 4 carriers [148].
PA was also associated with greater functional activity in the left caudate in MCI patients
[64], which may indicate preservation of caudate functioning and possibly a reduced risk for
conversion from MCI to AD.. These studies, combined with research from other groups,
suggest that the use of semantic processing tasks during fMRI may be a promising
presymptomatic biomarker of future cognitive decline. Optimal use of such a task may
require integration with other relevant variables, such as sMRI measures, APOE genotyping,
assessment of habitual or lifetime PA, or other biomarkers of AD [16].
4.2 Future longitudinal prediction
The prediction models derived from our longitudinal cohort [48, 148] were based on
baseline and 18-month follow-up neuropsychological assessments. This timeframe may be
somewhat brief for detecting clinically significant cognitive impairment; indeed, only two of
our declining participants met Petersen criteria for MCI [131]. We are now completing
neuropsychological follow-up for our original participants five years after baseline. Analysis
of these longer-term data will enable us to develop more powerful models using baseline
task-activated fMRI to predict cognitive decline more accurately. The utilization of three
time points will also permit the development of prediction models for assessing multiple
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trajectories of cognitive decline. For example, if a participant was cognitively stable at 18-
month follow-up but demonstrated decline after five years, is this pattern detectable at
baseline? Likewise, if a participant declines from baseline to 18 months but does not decline
further at five years, can this pattern be predicted from baseline data? Additional follow-up
intervals may eventually permit further refinement of a prediction model of the risk for AD
in cognitively intact, asymptomatic older adults using fMRI activation during semantic
memory processing tasks.
Other variables associated with the risk for developing AD can be added to our sMRI, fMRI,
and genotype models to further optimize prediction. Thus, we can determine whether our
identified predictors contain independent or overlapping information pertaining to risk for
cognitive decline. Recently, we reported that self-report measures of PA (but not self-
reported participation in cognitively stimulating activities) can enhance prediction of
cognitive decline [148]. An upcoming project involves the addition of blood plasma levels
of homocysteine, folate, and vitamin B12 to our prediction model. All three measures have
been implicated in risk for developing dementia [155, 156].
4.3 Issues with the clinical adaptation of fMRI for the assessment of risk
We have proposed that fMRI in conjunction with other markers of AD risk may be a
valuable model for preclinical prediction of future cognitive decline. However, several
methodological issues associated with fMRI may limit its clinical utility. First and foremost,
between-site standardization may be the largest hindrance preventing the development of
normative data for widespread usage [157]. It has been demonstrated that when an
individual is scanned with the same paradigm at multiple sites, there is substantial
fluctuation in the spatial extent of the obtained BOLD signal [158]. Factors that contribute to
this variability include magnet manufacturer, the method for sampling image information,
the software used to construct the image, the type of paradigm used, and perhaps most
importantly, magnet strength [157]. High field strength (i.e. 3.0 Tesla or greater) appears to
yield the best between-site reproducibility [158].
Furthermore, the image processing time necessary for functional data can contribute to
additional expense. Given that the maximally effective prediction model would include
other relevant (and perhaps costly) variables such as APOE genotyping, blood serum
measurements, and sMRI volumetrics, the total price tag of such a procedure may limit
accessibility. Patient motivation in the scanner may also be a relevant factor that can
influence the BOLD signal and/or behavioral performance and reduce within-subject
reliability. The presence of medical conditions such as hypertension, diabetes, or
hyperlipidemia (as well as medications associated with these conditions) may also influence
activation patterns and further complicate the establishment of usable norms [157, 159].
Dietary intake of common substances such as caffeine [160–162] and nicotine [163–165], or
the presence of psychological comorbidities such as depression [166, 167], anxiety disorders
[168–170], or psychosis [171, 172] also need to be accounted for when interpreting fMRI
data. Thus, while research studies have been successful in demonstrating fMRI’s ability to
assist in the prediction of cognitive decline, the adaptation to clinical settings may require
rigorous standardization.
4.4 Conclusion
Targeted intervention towards those at greatest risk is currently the most promising strategy
for anticipating and minimizing the burden of AD. Great advances have been made in
identifying lifestyle behaviors, biological measurements, and neuroimaging biomarkers that
are associated with risk for dementia. Task-activated fMRI during semantic memory
processing may be a promising biomarker of future cognitive decline. The FNDT can be
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completed even by individuals with MCI, and task performance generally remains high [60].
Semantic memory processing tasks, in conjunction with other risk factors or biomarkers,
may provide a sensitive and comprehensive estimate of an individual’s risk for late-life
cognitive decline and dementia. Further longitudinal research will produce additional
preclinical prediction strategies that can make the most effective use of emerging
intervention strategies for AD.
Highlights
1. Person identity presents an opportunity to study semantic memories of different
ages
2. Semantic processing tasks may function as an fMRI biomarker for cognitive
decline
3. Semantic tasks present advantages over episodic tasks for studying aging and
AD risk
4. Optimal prediction of risk may include a combination of variables
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Figure 1.
From reference [62]. Temporally graded MTL activation during the FNDT. (A) Anatomical
maps of MTL structures for a typical cognitively intact older participant. (B) Hemodynamic
response functions for recent (90s) and remote (50s) famous names and foils (FO). Note the
temporal gradient present in the right MTL structures. Area under the curve (AUC) analyses
between four and eight seconds post stimulus onset revealed greater activation for recent
compared to remote famous names in both the right hippocampal complex and
parahippocampal gyrus. Error bars reflect the standard error of the mean. Figure reproduced
with permission.
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Figure 2.
From reference [61]. Temporally graded neocortical activation during the FNDT. Four
regions that demonstrated evidence of a temporally graded response to names from different
time epochs are depicted with anatomical localization and full time-course, group-averaged
hemodynamic response functions (HRFs). Significant time epoch differences were identified
using estimates of the hemodynamic response (AUC for 4–8 sec poststimulus). Error bars
reflect the standard error of measurement at each time point. Figure reproduced with
permission.
Sugarman et al. Page 28
Biochim Biophys Acta. Author manuscript; available in PMC 2013 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
From reference [52]. Effects of risk factors for AD on the functional memory recruitment
during famous compared to unfamiliar names. Note the greater activation for unfamiliar
names in control (CON) participants and the opposite patterns in the at-risk groups (FH and
FH+ε4). Also note the dose-dependent effects of risk factors on recruitment, with the
greatest activation observed in the FH+ε4 group. Figure reproduced with permission.
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Figure 4.
From reference [48]. Baseline fMRI activation used in the prediction model of cognitive
decline, highlighting group differences in activation derived from the comparison of the
famous and unfamiliar names conditions: Famous > Unfamiliar is in red, Unfamiliar >
Famous in blue. Note the greater spatial extent of activation in the Famous > Unfamiliar
names comparison in the Stable compared to the Declining group. Figure reproduced with
permission.
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Figure 5.
From reference [63]. Effects of physical activity (PA) and risk for AD (APOE ε4 allele) on
functional recruitment in cognitively intact older adults. 15 functional regions of interest are
identified in the left panel with region numbers (R#). Bar graphs represent mean percent MR
signal intensity change for Famous > Unfamiliar name contrasts, for the main effects of PA
(panel A) and Risk (panel B) and the interaction effect of PA × Risk (panel C). Post-hoc
group differences are indicated by brackets in panel C (p < .001). Error bars reflect the
standard error of the mean. Figure reproduced with permission.
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